Qlife Completes Study Evaluating New Uses for Egoo Platform

Qlife Holding AB has finalized a customer-funded feasibility study designed to evaluate the Egoo® platform's potential in a new therapeutic area that necessitates consistent biomarker monitoring. The study's completion marks a step forward in showcasing the platform's adaptability.

Initiated as announced on June 1, 2026, the study was conducted with a global pharmaceutical company as planned. This collaboration aimed to demonstrate the Egoo platform's capability to accurately measure biomarkers from a finger-prick blood sample, enabling regular monitoring outside of a clinical setting.

The findings suggest the Egoo platform's potential to extend beyond its current development programs. This successful assessment of its applicability in a new domain highlights its broader utility in healthcare.

Qlife continues its efforts to commercialize the Egoo platform, seeking further partnerships and exploring new applications to enhance diagnostics and patient monitoring.